NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN
WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA,
JAPAN, HONG KONG OR THE UNITED STATES
(Oslo, Norway, 17 October 2016) Reference is made
to the stock exchange announcement dated 30 September 2016 and the
prospectus dated 30 September 2016 (the "Prospectus") concerning,
inter alia, the subsequent offering (the "Subsequent Offering") of
minimum 1 and maximum 13,333,334 new shares (the "Offer Shares") in
Hofseth BioCare ASA ("HBC" or the "Company", ticker "HBC"). The
subscription price in the Subsequent Offering is NOK 1.50, equal to
the subscription price in the NOK 165.4 million private placements
completed on 20 September 2016.
The subscription period for the subsequent Repair
Offering will end today, 17 October 2016 at 16:30 CET.
The period for trading in subscription rights
(ticker "HBC-T") for the Subsequent Offering will also expire
today, 17 October 2016 at 16:30 CET.
Subscription Rights that are not exercised before
the end of the subscription period will have no value and will
lapse without compensation to the holder. Holders of Subscription
Rights should note that subscriptions for Offer Shares must be made
in accordance with the procedures set out in the Prospectus and
that holding Subscription Rights in itself does not represent a
subscription for Offer Shares.
You are strongly encouraged to read the Prospectus
carefully before deciding if you would like to subscribe in the
Subsequent Offering. The Prospectus and the subscription form for
the Subsequent Offering is available at the company's website,
www.hofsethbiocare.no and in hard copy at the Company's premises at
Molovegen 6, 6004 Ålesund, Norway. The form can be downloaded from
this URL:
http://www.hofsethbiocare.no/upload_images/A66EB1AAE0CB44A8830C04AA60A11489.pdf
For further information, please contact:
Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no
About Hofseth BioCare:
Hofseth BioCare is a Norwegian biotech company that offers
high-value ingredients and finished products for humans and pets.
The company is founded on the core values of sustainability,
traceability and optimal utilization of natural resources. Through
an innovative hydrolysis technology, HBC is able to preserve the
quality of salmon oil, proteins and calcium, prepared of fresh
salmon off-cuts. HBC's objective is to contribute to the efficient
use of marine resources and deliver quality products for
ingredients and finished consumer products in the nutrition
market.
Hofseth BioCare's headquarters are located in
Ålesund, Norway with branches in Oslo, Chicago, Mumbai and Tokyo.
HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC".
More information about Hofseth BioCare at www.hofsethbiocare.com
and www.facebook.com/hofsethbiocare
This information is subject of the disclosure
requirements pursuant to section 5-12 of the Norwegian Securities
Trading Act.